Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Spruce Biosciences ( (SPRB) ) has issued an update.
On October 15, 2025, Bali Muralidhar, Ph.D. resigned from Spruce Biosciences‘ board of directors and its compensation committee. His departure was not due to any disagreements with the company’s operations or policies.
The most recent analyst rating on (SPRB) stock is a Hold with a $10.00 price target. To see the full list of analyst forecasts on Spruce Biosciences stock, see the SPRB Stock Forecast page.
Spark’s Take on SPRB Stock
According to Spark, TipRanks’ AI Analyst, SPRB is a Underperform.
Spruce Biosciences faces substantial financial challenges with declining revenues and persistent losses. Bearish technical indicators and unfavorable valuation metrics further weigh on the stock. The strategic acquisition of TA-ERT offers potential growth, but the financial instability remains a critical concern.
To see Spark’s full report on SPRB stock, click here.
More about Spruce Biosciences
Average Trading Volume: 463,070
Technical Sentiment Signal: Buy
Current Market Cap: $88.18M
See more data about SPRB stock on TipRanks’ Stock Analysis page.